Description

Natera’s $100 Million Early Cancer Detection Bet Opens A Much Bigger Long-Term Market!

Natera’s second quarter of 2026 results demonstrate continued growth and operational progress across its key business segments: oncology, women’s health, and organ health. The company processed a record 1,044,000 tests during the quarter, with clinical Minimal Residual Disease (MRD) oncology tests increasing approximately 56% year-over-year to 283,000 units, including the largest sequential increase recorded at 34,000 units above the prior quarter. These volumes contributed to approximately $753 million in revenue, representing a 38% increase compared to Q2 2025, or 40% excluding revenue true-ups. Gross margins improved sequentially to about 65%, driven in part by higher average selling prices (ASPs), notably for the Signatera MRD test, which continues to benefit from growing Medicare Advantage and commercial plan reimbursement.